Skip to main content

Table 1 Medicines identified as potential MES candidates since introduction of formal MES policy in January-2011 [35]

From: A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma

Medicinea

MES

Ipilimumab for metastatic melanoma (2012)

• Pay for performance with rebates payable should 2 year overall survival rates in real world clinical practice in Australia not align with clinical trial data

Ivacaftor for cystic fibrosis (2014)

• Pay for performance with rebates applicable for patients subsequently assessed as non-responders

Eculizumab for atypical haemolytic uraemic syndrome (2014)

• Pay for performance with rebates applicable for patients who do not achieve an agreed clinical outcome over an agreed time periods

Trametinib for metastatic melanoma (2014)

• Pay for performance with rebates applicable should trametinib fail to deliver claimed benefits

Crizotinib for non-small cell lung cancer (2014)

• Pay for performance with rebates applicable should crizotinib fail to deliver claimed benefits

Pembrolizumab for metastatic melanoma (2015)

• PBS list with provision for future clinical trial evidence to support a potential price increase

Nivolumab for non-small cell lung cancer (2016)

• PBS list with provision of future evidence to confirm effectiveness of nivolumab in NSCLC patients ≥75 years of age

  1. aMedicines considered by the PBAC between January 2011 and November 2016